RAM
NKTR icon

Readystate Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Readystate Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-45,042
Closed -$2.56M – 445
2025
Q3 		$2.56M Buy
+45,042
New +$1.49M 0.11% 130

Other funds holding NKTR

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Readystate Asset Management's NKTR Position: Q4 2025 in Review

Readystate Asset Management sold out of Nektar Therapeutics (NKTR) in Q4 2025, closing a stake of 45,042 shares — an estimated $2.56M sold.

Readystate Asset Management first reported a position in NKTR in Q3 2025 and held it in 1 quarter. The position peaked at $2.56M in Q3 2025. 180 funds tracked by Wall St. Rank hold NKTR as of Q4 2025.

  • Readystate Asset Management reported no remaining Nektar Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Readystate Asset Management sold 45,042 Nektar Therapeutics shares in Q4 2025, an estimated $2.56M.
  • Readystate Asset Management first reported a position in Nektar Therapeutics in Q3 2025 and held it in 1 quarter.
  • Readystate Asset Management's Nektar Therapeutics position peaked at $2.56M in Q3 2025.
  • 180 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2025.

Based on Readystate Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.